Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
kdm3
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "kdm3" in MCE Product Catalog:
16
Target:
Research Areas:
IOX1, a chemical probe, is a potent broad‐spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases. IOX1 inhibits KDM4C, KDM4E, KDM2A, KDM3A and KDM6B with IC50 values of 0.6 μM, 2.3 μM, 1.8 μM, 0.1 μM and 1.4 μM, respectively . IOX1 also inhibits ALKBH5 [3].
1
1 Cited Publications
Target:
Research Areas:
PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits PAX3-FOXO1 action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).
Cat. No.: HY-168593
CAS No.: 3119090-33-1
Target:
Research Areas:
PROTAC KDM3 degrader-1 is a KDM3A/KDM3B PROTAC degrader with DC50 values of 13.73 nM and 172.6 nM in SW480 cells, respectively. PROTAC KDM3 degrader-1 induces cereblon-dependent proteasomal degradation of KDM3A and KDM3B. PROTAC KDM3 degrader-1 inhibits the oncogenic Wnt/β-catenin signaling pathway. PROTAC KDM3 degrader-1 eliminates colorectal cancer stem cells, suppresses their self-renewal, and blocks colony formation of colorectal cancer cells. PROTAC KDM3 degrader-1 inhibits tumor growth in a colorectal cancer xenograft mouse model. PROTAC KDM3 degrader-1 can be used for the research of colorectal cancer .
Cat. No.: HY-162301
CAS No.: 931596-95-1
Target:
Research Areas:
P3FI-63 is a KDM3B inhibitor with a IC50 value of 7 μM. P3FI-63 has antitumor activity .
Cat. No.: HY-RS07211
Target:
Research Areas:
KDM3A Human Pre-designed siRNA Set A contains three designed siRNAs for KDM3A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS07212
Target:
Research Areas:
KDM3B Human Pre-designed siRNA Set A contains three designed siRNAs for KDM3B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS17111
Target:
Research Areas:
Kdm3a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kdm3a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS24653
Target:
Research Areas:
Kdm3b Rat Pre-designed siRNA Set A contains three designed siRNAs for Kdm3b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23556
Target:
Research Areas:
Kdm3a Rat Pre-designed siRNA Set A contains three designed siRNAs for Kdm3a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS18179
Target:
Research Areas:
Kdm3b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kdm3b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P71585
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: kdm3B; Lysine (K)-Specific Demethylase 3B; Prev. C5orf7; Jumonji Domain Containing 1B; Prev. JMJD1B; Nuclear Protein 5qNCA; KIAA1082; Chromosome 5 Open Reading Frame 7; NET22; JHDM2B; JmjC Domain-Containing Histone Demethylation Protein 2B; 5qNCA; [Histon
Cat. No.: HY-P86931
Synonyms: 5qNCA antibody; C5orf7 antibody; JHDM2B antibody; JmjC domain containing histone demethylation protein 2B antibody; JmjC domain-containing histone demethylation protein 2B antibody; jmjd1b antibody; Jumonji domain containing 1B antibody; Jumonji domain containing protein 1B antibody; Jumonji domain-containing protein 1B antibody; kdm3B antibody; 5qNCA antibody; C5orf7 antibody; JHDM2B antibody; JmjC domain containing histone demethylation protein 2B antibody; JmjC domain-containing histone demethylation protein 2B antibody; jmjd1b antibody; Jumonji domain containing 1B antibody; Jumonji domain containing protein 1B antibody; Jumonji domain-containing protein 1B antibody; kdm3B antibody; kdm3B_HUMAN antibody; KIAA1082 antibody; Lysine (K) specific demethylase 3B antibody; Lysine-specific demethylase 3B antibody; NET22 antibody; Nuclear protein 5qNCA antibody;
Cat. No.: HY-183618
Target:
Research Areas:
DW-229 is a PROTAC degrader derived from Deferiprone (HY-B0568), targeting Fe(II)/α‑ketoglutarate‑dependent histone lysine demethylases (KDMs). DW-229 degrades KDM2A, KDM3A, KDM5B, KDM4A‑C, KDM5C, KDM6B in breast cancer cells. DW-229 shows IC50 < 0.5 μM against MCF‑7 cells and IC50 of 8.87 μM against MDA‑MB‑231 cells, with high cancer cell selectivity. DW-229 can be used for the research of breast cancer, liver cancer, prostate cancer, lung cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
